Research programme: hepatitis C virus protease inhibitors - InterMune
Alternative Names: ITMN A; ITMN-5489; Second-generation HCV protease inhibitors - InterMuneLatest Information Update: 02 Aug 2019
At a glance
- Originator Array BioPharma; InterMune
- Developer InterMune; Roche
- Class Small molecules
- Mechanism of Action Hepatitis C protease inhibitors; Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 30 Jul 2019 Array Biopharma has been acquired by Pfizer
- 30 Jun 2011 Discontinued - Preclinical for Hepatitis C in USA (PO)
- 13 Apr 2010 Preclinical development is ongoing in USA